Category Archives: Tri-State News

Winners of the 2014 Donald W. Reynolds Tri-State Competition Named

BioBotic Solutions Takes Second Place Undergraduate Award

Second Place, Undergraduate — BioBotic Solutions, University of Arkansas & Hendrix College

Second Place, Undergraduate — BioBotic Solutions, University of Arkansas & Hendrix College

The Arkansas Economic Acceleration Foundation, an affiliate of The Arkansas Capital Corporation Group, is pleased to announce BioBotic Solutions with team members from University of Arkansas and Hendrix College took second place in the Donald W. Reynolds Tri-State Award competition. The competition was held at The Mirage of Las Vegas.

In the undergraduate track, Owlpal Healthcare from the University of Tulsa took first place. In the graduate track, Dragonfly Energy from University of Nevada, Reno, was awarded first place, and Driven Analytics from University of Oklahoma, Norman, was awarded second place.

First place winners took home a $30,000 cash prize, a team trophy and individual plaques. The second place winners received a $20,000 prize, a trophy and individual plaques. The teams’ faculty advisors each earned a $3,500 check.

“This year’s teams pitched sophisticated and forward-thinking business plans that have the potential to become very successful companies,” said Rush Deacon, acting chief executive officer for Arkansas Capital Corporation. “It’s exactly the type of innovation we were looking for when we started this competition. This competition is an example of broad efforts Arkansas Capital Corporation has spearheaded to support entrepreneurship in Arkansas, and we are very proud of our student competitors.” Continue reading

BiologicsMD Names David Owens CEO

David Owens

David Owens

Fayetteville pharmaceutical development firm BiologicsMD has named David Owens its first CEO.

BiologicsMD is a portfolio company of VIC Technology Venture Development, which had previously managed its operations.

Most recently, Owens was chief business officer for Novira Therapeutics, an antiviral drug discovery company based in Doylestown, Pa. In March, Novira completed a $25 million Series A financing round.

BiologicsMD has developed an osteoporosis treatment, PTH-CBD, that binds to the bone and stimulates new bone growth.

“I’m very excited to join the BiologicsMD team at this very important stage in advancing the company’s lead development drug, PTH-CBD, towards the clinic,” Owens said in a news release. Continue reading

Movista Receives $82,000 Investment from ASTA

Movista co-founders Stan Zylowski and April Seggebrush (Photo by Beth Hall)

Movista co-founders Stan Zylowski and April Seggebrush (Photo by Beth Hall)

Bentonville retail software firm Movista has received an $82,959 investment from the Arkansas Science & Technology Authority.

The funds will be used to commercialize Movista’s proprietary technology, which provides retail tracking, verifying and reporting activities, according to a news release. The funds will come from ASTA’s Seed Capital Investment Program.

Movista is an Innovate Arkansas client firm. ASTA recently invested in another IA company, Angel Eye Camera Systems of Little Rock. Continue reading

Picasolar Ties for Second at National Clean Energy Contest

PicasolarUniversity of Arkansas startup Picasolar, which developed a way to make solar cells more efficient, tied for second at the National Clean Energy Business Plan Competition this week in Washington, D.C.

The event, in its second year, is put on by the U.S. Department of Energy and brings together six regional winners from across the country. Winners were announced on Tuesday, and SiNode Systems from Northwestern University was the overall winner. Continue reading

BiologicsMD Signs Deal to Make Its Osteoporosis Treatment

Fayetteville drug development startup BiologicsMD announced on Tuesday a partnership with an Oklahoma firm that will make the company’s osteoporosis treatment.

BioMD, which has developed what it considers a breakthrough treatment for the disease called PTH-CBD, has contracted with Cytovance Biologics of Oklahoma City to develop a manufacturing platform for the drug.

In addition, the firm has welcomed its newest board member, Ensysce Biosciences CEO Lynn Kirkpatrick, to help guide it through the Food and Drug Administration approval process. Continue reading